Celldex Therapeutics
As of the edition of 20 October 2026, Celldex Therapeutics runs 20 drugs; it is on route A at 15 targets and on route B at 0 targets.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Family history
The records place 2 company names in this family.
- CuraGen Corporation: acquired in 2009; successor Celldex Therapeutics
Drugs by status
| Status | Count |
|---|---|
| Active | 3 |
| Went quiet | 6 |
| Stopped | 9 |
| Status not established | 2 |
| Total | 20 |
Where it needs a new molecule
Route A at 15 targets, route B at 0 targets.
All 15 rows on route A or B
In the product15 company-target rows on route A or B; 12 are not shown here, and no score is.
See all 15 targets where Celldex Therapeutics needs a new molecule, with the facts behind eachRequest access. Nothing is shown until you do.
Where its trials are
- Skin and connective tissue: 23 trials led
- Cancer: 22 trials led
- Immune system: 14 trials led